Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
Bristol-Myers Squibb (BRM) Stock Price & Analysis
14 Followers
BRM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€43.19 - €61.94
Previous Close€46.16
Volume988.00
Average Volume (3M)2.38K
Market Cap
€92.70B
Enterprise Value€135.72B
Total Cash (Recent Filing)$9.67B
Total Debt (Recent Filing)$55.68B
Price to Earnings (P/E)N/A
Beta0.07
Next Earnings
Jul 26, 2024EPS Estimate
€1.57Last Dividend Ex-Date
Apr 04, 2024Dividend Yield4.71%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,022,193,411
10 Day Avg. Volume3,820
30 Day Avg. Volume2,383
Standard Deviation0.06
R-Squared0.06
Alpha0.00641
Financial Highlights & Ratios
Price to Book (P/B)-5.24
Price to Sales (P/S)7.17
Price to Cash Flow (P/CF)5.80
P/FCF Ratio5.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.00
Enterprise Value/Gross Profit3.96
Enterprise Value/Ebitda32.82
Forecast
1Y Price Target
€49.74Price Target Upside17.57% Upside
Rating ConsensusHold
Number of Analyst Covering15
Bristol-Myers Squibb News
PremiumCompany Announcements
Bristol-Myers Squibb Q1 Earnings Call Strategy Insights
Bulls Say, Bears Say
Bulls Say
Company PerformanceBristol's recent earnings report shows significant revenue and EPS beats, driven by strong sales from popular products like Eliquis and Revlimid.
Drug DevelopmentKarXT continues to demonstrate long-term efficacy and safety, with new data supporting its sustained use and favorable benefit-risk profile, which could lead to increased market confidence and approval odds.
Stock ValuationWith analysts indicating a price objective higher than the current stock price and BMY shares considered undervalued, there appears to be a potential upside for investors.
Bears Say
Debt ConcernsThe company's net debt to equity ratio is high, reflecting a significant level of debt relative to shareholder equity.
Financial PerformanceAdjusted EPS for the first quarter is significantly lower than the previous year, indicating a decline in profitability.
Product Sales ConcernsOpdivo could miss sales expectations due to buying patterns and weak script performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.30% Insiders
24.11% Mutual Funds
24.22% Other Institutional Investors
51.36% Public Companies and
Individual Investors
BRM FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €43.19 and its highest was €61.94 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Jul 26, 2024 which is in 90 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Apr 25, 2024. The company reported -€4.109 earnings per share for the quarter, beating the consensus estimate of -€4.12 by €0.011.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of €0.56 which represents an annual dividend yield of 4.71%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is €1.57.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,026,758,700 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of -€4.109 in its last earnings report, beating expectations of -€4.12. Following the earnings report the stock price went down -7.776%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 1B.
---
Bristol-Myers Squibb Stock Smart Score
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BRM Company Deck
---
BRM Earnings Call
Q1 2024
0:00 / 0:00
---
BRM Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BRM Stock 12 Months Forecast
Average Price Target
€49.74
▲(17.57% Upside)
Technical Analysis
Best Analysts Covering BRM
1 Year
1 Year Success Rate
15/16 ratings generated profit
1 Year Average Return
+14.39%
reiterated a sell rating 18 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +14.39% per trade.
---